Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INDP Indaptus Therapeutics, Inc.

Pre-Mkt 02-19 07:12:55 EST

1.87

+0.06

+3.48%

High1.96	Low1.84	Vol32.83K
Open1.88	D1 Closing1.81	Amplitude6.63%
Mkt Cap4.20M	Tradable Cap1.85M	Total Shares2.24M
T/O62.77K	T/O Rate3.33%	Tradable Shares985.10K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INDP","market":"US","secType":"STK","nameCN":"Indaptus Therapeutics, Inc.","latestPrice":1.873,"timestamp":1771448400000,"preClose":1.81,"halted":0,"volume":32830,"delay":0,"changeRate":0.03480662983425411,"floatShares":985100,"shares":2242300,"eps":-29.03,"marketStatus":"Pre-Mkt","change":0.063,"latestTime":"02-19 07:12:55 EST","open":1.8799,"high":1.96,"low":1.84,"amount":62771.255470000004,"amplitude":0.066298,"askPrice":2.16,"askSize":200,"bidPrice":1.65,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-29.03,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771511400000},"marketStatusCode":1,"adr":0,"listingDate":1438660800000,"exchange":"NASDAQ","adjPreClose":1.905,"postHourTrading":{"tag":"盘后","latestPrice":1.873,"preClose":1.873,"latestTime":"16:57 EST","volume":34,"amount":61.6935,"timestamp":1771451852756,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1378602792263306},"requestUrl":"/m/hq/s/INDP","defaultTab":"news","newsList":[{"id":"2610192204","title":"Indaptus Therapeutics Cuts Warrant Exercise Prices to $1.75 in Unregistered Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2610192204","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610192204?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:31","pubTimestamp":1770906664,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. announced that it has entered into agreements to reprice certain outstanding warrants originally issued in financing rounds during 2024 and 2025. The exercise prices of these warrants, covering an aggregate of 913,638 shares of common stock, were reduced to $1.75 per share, in line with Nasdaq’s minimum price rules. In connection with this repricing, holders agreed to vote their shares in favor of all proposals at the upcoming special stockholder meeting. Additionally, the company’s board of directors unilaterally reduced the exercise prices of remaining warrants and placement agent warrants for 762,787 shares to $1.75 per share. These transactions constitute unregistered sales of equity securities. All other warrant terms remain unchanged.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL6JpD5R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2605436149","title":"Indaptus Therapeutics Cuts Executive Officer Salaries to $60,000 Per Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2605436149","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605436149?lang=en_us&edition=fundamental","pubTime":"2026-01-21 05:08","pubTimestamp":1768943302,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. has announced adjustments to the compensation of its executive officers. Effective January 15, 2026, the annual salaries of Co-Chief Executive Officer Jeffrey A. Meckler and Chief Science Officer Michael J. Newman have been set at $60,000 for the remainder of the year, as outlined in newly executed salary adjustment agreements. These agreements follow previous employment modifications related to the company's securities purchase agreement with investor David E. Lazar.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL4dYjPD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2603526322","title":"Indaptus Therapeutics Files Initial Statement of Beneficial Ownership for Director David Natan","url":"https://stock-news.laohu8.com/highlight/detail?id=2603526322","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603526322?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:05","pubTimestamp":1768251943,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists David Natan as the beneficial owner in his role as Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6VkGgB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Indaptus Therapeutics Files Initial Statement of Beneficial Ownership for Director David Natan","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2602315744","title":"Indaptus Therapeutics Appoints David Natan to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2602315744","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602315744?lang=en_us&edition=fundamental","pubTime":"2026-01-09 06:26","pubTimestamp":1767911214,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. has expanded its Board of Directors from eight to nine members and appointed David Natan as a Class II director. Natan will also serve on the Audit Committee, replacing Avraham Ben-Tzvi, who will continue as a director and become a paid consultant.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL6nfCsV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2602277315","title":"Indaptus Therapeutics Inc. Announces Date for Special Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2602277315","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602277315?lang=en_us&edition=fundamental","pubTime":"2026-01-09 06:23","pubTimestamp":1767911027,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. has announced that it will hold a Special Meeting of Stockholders on February 17, 2026, at its offices in New York, NY. The meeting will address specific matters for stockholder consideration as outlined in the accompanying notice and proxy statement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL2R7h6k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2601388704","title":"BRIEF-Indupro Therapeutics Announces Strategic Collaboration With Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2601388704","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601388704?lang=en_us&edition=fundamental","pubTime":"2026-01-08 02:18","pubTimestamp":1767809893,"startTime":"0","endTime":"0","summary":"BRIEF-Indupro Therapeutics Announces Strategic Collaboration With LillyJan 7 (Reuters) - Indupro Therapeutics:INDUPRO THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP FIRST-IN-CLAS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y80UG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0323591593.USD","LU0820561818.USD","LU0266013472.USD","LU1069344957.HKD","LU0708995401.HKD","LU2750360641.GBP","SG9999014880.SGD","LU0203202063.USD","LU1127390331.HKD","SG9999017495.SGD","LU0889565916.HKD","LU2361044949.HKD","LU2602419157.SGD","LU0109391861.USD","LU0882574055.USD","LU1280957306.USD","LU2168563687.JPY","IE00BJJMRY28.SGD","LU0114720955.EUR","LU2417539215.USD","LU2237443549.SGD","IE00BWXC8680.SGD","LU0289739699.SGD","LU1974910355.USD","LU0432979614.USD","SG9999014898.SGD","LU0122379950.USD","IE00B2B36J28.USD","LU0640476718.USD","LU2360106947.USD","LU0823434740.USD","LU1323610961.USD","LU2265009873.SGD","LU1035775433.USD","IE00BJT1NW94.SGD","LU1868836914.USD","LU1983299246.USD","IE00B1XK9C88.USD","LU0683600562.USD","LU2063271972.USD","LU0094547139.USD","SGXZ57979304.SGD","INDP","LU0787776722.HKD","LU0672654240.SGD","IE0002141913.USD","IE00B7KXQ091.USD","IE0004445239.USD","LU0109394709.USD","LU0354030511.USD","BK4599","LU2236285917.USD","LU2237443465.HKD","LU2361045086.USD","LU1720051017.SGD","LU2491049909.HKD","LU2462157665.USD","LU2108987350.USD","LU2087625088.SGD","IE00BFSS8Q28.SGD","LLY","IE00B775H168.HKD","LU0097036916.USD","LU0471298777.SGD","IE00B1BXHZ80.USD","IE00BJJMRX11.SGD","LU1267930730.SGD","LU2471134952.CNY","IE0009355771.USD","IE00BFTCPJ56.SGD","SG9999018865.SGD","LU1814569148.SGD","LU1868837136.USD","LU2324357040.USD","SGXZ81514606.USD","IE00BJJMRZ35.SGD","LU1712237335.SGD","IE00BJLML261.HKD","LU0061475181.USD","LU0320765059.SGD","BK4516","LU2211815571.USD","LU0820561909.HKD","LU0079474960.USD","LU1061106388.HKD","LU2456880835.USD","LU1989771016.USD","LU2468319806.SGD","LU1868836591.USD","LU1023059063.AUD","LU2461242641.AUD","LU0234572021.USD","IE00B4JS1V06.HKD","LU0320765992.SGD","IE00BKPKM429.USD","LU0106261372.USD","LU1868837300.USD","LU2552382058.USD","SGXZ51526630.SGD","LU2471134879.HKD","LU2168564495.EUR","LU2237443978.SGD","SG9999015986.USD","LU2237443382.USD","LU1720051108.HKD","BK4007","LU1548497426.USD","LU2106854487.HKD","LU2471134523.USD","LU2552382215.SGD","SG9999001176.USD","SGXZ99366536.SGD","LU0353189680.USD","LU2168564065.EUR","LU2168564149.EUR","LU2357305700.SGD","LU1551013425.SGD","LU0882574139.USD","LU0823416689.USD","LU1291159041.SGD","LU0471298694.HKD","BK4534","LU2023250504.SGD","LU0096364046.USD","LU0456855351.SGD","LU2750360997.AUD","LU2552382132.HKD","IE00BK4W5M84.HKD","LU2471134796.USD","LU0316494557.USD","LU0238689110.USD","SGXZ31699556.SGD","SG9999013999.USD","LU1804176565.USD","LU0256863811.USD","LU1623119135.USD","LU2264538146.SGD","IE00BK4W5L77.USD","SG9999015978.USD","IE00B4R5TH58.HKD","LU2168564222.USD","SG9999015952.SGD","LU0943347566.SGD","LU0786609619.USD","LU0823434583.USD","LU0006306889.USD","BK4588","LU0353189763.USD","LU2237443895.HKD","LU1551013342.USD","SG9999014906.USD","LU0198837287.USD","IE00BN29S564.USD","LU0203201768.USD","LU0256863902.USD","LU2746668974.SGD","BK4581","BK4533","IE0004445015.USD","LU2237443622.USD","LU0417517546.SGD","LU1366192091.USD","SG9999015945.SGD","LU0689472784.USD","LU1868836757.USD","BK4585","LU0385154629.USD","LU2746668461.USD","LU0466842654.USD","LU2112291526.USD","LU2491050071.SGD","LU0354030438.USD","LU1917777945.USD","IE0005OL40V9.USD","LU1232071149.USD","LU1057294990.SGD","IE00BKDWB100.SGD","IE00BFSS7M15.SGD","LU2491050154.USD","SG9999018857.SGD","LU1093756168.USD","LU2237438978.USD","GB00BDT5M118.USD","LU2361044865.SGD","LU1093756325.SGD","LU1064131342.USD","LU1988902786.USD","SG9999001176.SGD","LU2089984988.USD","SG9999014914.USD","LU0058720904.USD"],"gpt_icon":1},{"id":"2600098751","title":"Indaptus Therapeutics Board Members Resign Pending Approval of New Nominees","url":"https://stock-news.laohu8.com/highlight/detail?id=2600098751","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600098751?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:06","pubTimestamp":1767387980,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. announced that board members Michael Newman, Mark Gilbert, and Anthony Maddaluna have submitted their resignations, effective upon the approval of David Lazar's nominees at the company's next stockholders' meeting. The company stated that the resignations were not due to any disagreements regarding its operations or management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDLbjlxXD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2595787874","title":"Indaptus Therapeutics Inc - David E. Lazar Appointed Co-CEO and Chairman of Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2595787874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595787874?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:00","pubTimestamp":1767009600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA4HFGD6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2595787860","title":"Indaptus Enters Into $6 Million Securities Purchase Agreement With Investor David E. Lazar","url":"https://stock-news.laohu8.com/highlight/detail?id=2595787860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595787860?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:00","pubTimestamp":1767009600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA4HFGD6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2593423587","title":"Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593423587","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593423587?lang=en_us&edition=fundamental","pubTime":"2025-12-24 11:12","pubTimestamp":1766545920,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics surged 64.65% in after-hours trading following a major insider investment and board appointment.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/23/Stock-Market-Analysis--Notebooks--Laptop.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/23/Stock-Market-Analysis--Notebooks--Laptop.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/12/49578047/why-did-indaptus-therapeutics-surge-64-in-after-hours-trading","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/12/49578047/why-did-indaptus-therapeutics-surge-64-in-after-hours-trading","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LENZ","KALA","BK4150","BK4007","BK4139","RSI","INDP","BK4539"],"gpt_icon":0},{"id":"2593847441","title":"Indaptus Therapeutics Files Initial Beneficial Ownership Statement for Director Avraham Ben-Tzvi","url":"https://stock-news.laohu8.com/highlight/detail?id=2593847441","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593847441?lang=en_us&edition=fundamental","pubTime":"2025-12-24 08:06","pubTimestamp":1766534802,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Avraham Ben-Tzvi as a director and the beneficial owner of securities in the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nNDL5Hq497:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Indaptus Therapeutics Files Initial Beneficial Ownership Statement for Director Avraham Ben-Tzvi","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2593449513","title":"Indaptus' Stock Up After Lazar Agrees to Buy 1M Shares, Become Co-CEO and Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2593449513","media":"Dow Jones","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593449513?lang=en_us&edition=fundamental","pubTime":"2025-12-24 07:22","pubTimestamp":1766532120,"startTime":"0","endTime":"0","summary":"Shares of Indaptus Therapeutics rose after David Lazar agreed to buy 1 million shares and become co-chief executive officer and chair of the cancer-treatment company.The stock climbed 58% to $3.09 in after-hours trading Tuesday. Through the close, the stock had lost 92% of its value this year.Indaptus entered into a securities purchase agreement with Lazar, who agreed to buy shares from the company at a price of $6 each, for total gross proceeds of $6 million.The purchase will include 300,000 shares of Series AA convertible preferred stock and 700,000 shares of Series AAA convertible preferred stock.The company plans to use proceeds from the sale for severance, general corporate and working capital purposes.In connection with the deal, Indaptus named Lazar as co-chief executive and chair of the board effective immediately prior to closing. Outgoing Chair Roger Pomerantz will continue to serve as a board member.As long as he continues owning more than 10% of Indaptus's shares, Lazar wil","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Indaptus' Stock Up After Lazar Agrees to Buy 1M Shares, Become Co-CEO and Chair","news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2593446250","title":"BRIEF-Indaptus Therapeutics Inc - Appointed David Lazar As The Co-Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2593446250","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593446250?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:55","pubTimestamp":1766530518,"startTime":"0","endTime":"0","summary":"BRIEF-Indaptus Therapeutics Inc - Appointed David Lazar As The Co-Chief Executive OfficerDec 23  - Indaptus Therapeutics Inc INDP.O:INDAPTUS THERAPEUTICS INC - APPOINTED DAVID LAZAR AS THE CO-CHIEF EXECUTIVE OFFICERSource text: [ID:n0001493152-25-029107]Further company coverage: INDP.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0NH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2593446821","title":"Indaptus Therapeutics Inc - Appointed David Lazar as the Co-Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2593446821","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593446821?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:25","pubTimestamp":1766528738,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0NH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2583516290","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (INDP) and Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583516290","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583516290?lang=en_us&edition=fundamental","pubTime":"2025-11-14 03:40","pubTimestamp":1763062814,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Indaptus Therapeutics (INDP – Research Report) and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-indaptus-therapeutics-indp-and-fate-therapeutics-fate-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-indaptus-therapeutics-indp-and-fate-therapeutics-fate-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","FATE","BK4139","INDP","LU0029874061.USD","BK4137","BK4585","BK4588","XBI","HCSG","BK4581","LABU","XLV"],"gpt_icon":0},{"id":"2582374542","title":"Indaptus Therapeutics Q3 profit beats estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374542","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374542?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:38","pubTimestamp":1762954705,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Q3 profit beats estimatesOverviewIndaptus Q3 2025 EPS beats analyst expectations, improving from last year's lossCompany raised $2.3 mln through at-the-market facility, strengthe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0HI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2582374387","title":"Indaptus Therapeutics posts third quarter net loss of $2.98 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374387","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374387?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:31","pubTimestamp":1762954317,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. reported research and development expenses of approximately $1.5 million for the third quarter ended September 30, 2025, an increase of $0.1 million from the same period in 2024. Net cash used in operating activities was $11.6 million for the first nine months of 2025, compared to $8.9 million for the same period in 2024. Net cash provided by financing activities for the nine months ended September 30, 2025, included a $5.7 million private placement of convertible notes and warrants in June and $2.3 million raised in September through an at-the-market facility. Loss per share was $3.0 for the third quarter of 2025, compared to $9.0 for the third quarter of 2024. As of September 30, 2025, cash and cash equivalents totaled $5.8 million. The company completed the Safety Lead-In cohort of its Phase 1 combination trial with Decoy20 and tislelizumab, dosing six evaluable participants, with three achieving stable disease at the first assessment. Indaptus expects cur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLbtbj4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"gpt_icon":0},{"id":"2582337475","title":"Rpt-Indaptus Therapeutics Q3 EPS USD -2.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2582337475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582337475?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:30","pubTimestamp":1762954202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXB9930B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"gpt_icon":0},{"id":"2565500695","title":"Investors Await Key Jobs Data as US Futures Mixed in Friday's Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2565500695","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565500695?lang=en_us&edition=fundamental","pubTime":"2025-09-05 20:15","pubTimestamp":1757074520,"startTime":"0","endTime":"0","summary":"US stock futures are mixed in Friday's premarket session as investors look ahead to key employment reports, as well as oil industry data coming out later in the morning.The Dow Jones Industrial Average futures were off 0.2%, S&P 500 futures were up 0.1%, and Nasdaq futures were rising 0.5%.Oil prices were moving lower, with front-month global benchmarks Brent crude and West Texas Intermediate crude declining 1% and 1.1% respectively.In equities, shares of Twin Vee Powercats  soared 53% after gaining 6.7% the previous day. Hour Loop  shares jumped 53%, piling on to a 49%  gain from Thursday. And shares of Braze  advanced 21% after it reported fiscal Q2 adjusted earnings late Thursday that beat analysts expectations.On the losing side, shares of lululemon athletica  tumbled 20% after it said overnight that it is lowering its full-year financial outlook.  American Outdoor Brands  shares shed 15% after it reported late Thursday that it swung to a loss in Q1. And shares of Indaptus Therapeu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9d4bdd52063afd6dc2cca6bcc6d04835","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4190","LULU","BK4220","BRZE","HOUR","BK4211","LU1496350502.SGD","AOUT","BK4202","BK4139","BK4504","BK4122","LU0823411888.USD","BK4585","VEEE","BK4539","INDP","BK4588","BK4613","ISBC","BK4023"],"gpt_icon":1},{"id":"2565077083","title":"Indaptus Therapeutics Announces Promising Updates on Decoy20 and Tislelizumab Combination Therapy in Ongoing Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2565077083","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565077083?lang=en_us&edition=fundamental","pubTime":"2025-09-05 04:02","pubTimestamp":1757016150,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc. has announced updates on their ongoing INDP-D101 clinical trial involving the Decoy20 combination with the PD-1 inhibitor, tislelizumab. The trial, which is in the clinical stage, aims to explore innovative treatments for cancer and viral infections. The company has completed the monotherapy portion of the trial and initiated a cohort of seven patients for the combination therapy. Among the first three evaluable patients in the combination therapy, one patient exhibited stable disease at the first assessment, while two experienced disease progression. Additionally, a patient in the monotherapy study displayed a partial response with a reduction in liver metastases, although the disease progressed at the next imaging. Indaptus plans to continue dosing additional patients and will present further results in the coming weeks.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL7FVxNL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.indaptusrx.com","stockEarnings":[{"period":"1week","weight":0.0522},{"period":"1month","weight":-0.4539},{"period":"3month","weight":0.0703},{"period":"6month","weight":-0.7452},{"period":"1year","weight":-0.9131},{"period":"ytd","weight":-0.3564}],"compareEarnings":[{"period":"1week","weight":-0.0082},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1223},{"period":"ytd","weight":0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.037296},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.008726},{"month":3,"riseRate":0.5,"avgChangeRate":-0.057576},{"month":4,"riseRate":0.3,"avgChangeRate":-0.031116},{"month":5,"riseRate":0.4,"avgChangeRate":-0.05581},{"month":6,"riseRate":0.5,"avgChangeRate":-0.001521},{"month":7,"riseRate":0.4,"avgChangeRate":-0.067711},{"month":8,"riseRate":0.4,"avgChangeRate":0.036746},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.055501},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.090558},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.057102},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.026598}],"exchange":"NASDAQ","name":"Indaptus Therapeutics, Inc.","nameEN":"Indaptus Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Indaptus Therapeutics, Inc.(INDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Indaptus Therapeutics, Inc.,INDP,Indaptus Therapeutics, Inc.股票,Indaptus Therapeutics, Inc.股票老虎,Indaptus Therapeutics, Inc.股票老虎国际,Indaptus Therapeutics, Inc.行情,Indaptus Therapeutics, Inc.股票行情,Indaptus Therapeutics, Inc.股价,Indaptus Therapeutics, Inc.股市,Indaptus Therapeutics, Inc.股票价格,Indaptus Therapeutics, Inc.股票交易,Indaptus Therapeutics, Inc.股票购买,Indaptus Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Indaptus Therapeutics, Inc.(INDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction